Acta Scientific Veterinary Sciences (ISSN: 2582-3183)

Review Article Volume 4 Issue 11

miRNA: A Prospective Tool for Gene Regulation

Mayank Patel1, Subhash J Jakhesara1, Akash Golaviya1 and Prakash Koringa 2*

1Department of Animal Genetics and Breeding, College of Veterinary Science and A.H., Kamdhenu University, Anand, Gujarat, India
2Department of Animal Biotechnology, College of Veterinary Science and A.H., Kamdhenu University, Anand, Gujarat, India

*Corresponding Author: Prakash Koringa, Department of Animal Biotechnology, College of Veterinary Science and A.H., Kamdhenu University, Anand, Gujarat, India.

Received: September 28, 2022; Published: October 27, 2022


MicroRNAs (miRNAs) are endogenous small non-coding RNA molecules with an average of ~22 nucleotides in length, found in plants, animals and some viruses. In mammals, miRNA modulates gene expression either by translational repression or mRNA degradation. This is an essential regulatory mechanism to modulate fundamental cellular functions such as differentiation, proliferation, death, metabolism, and pathophysiology of many diseases. In this review, we explore the involvement of several elements in miRNAs pathways as well as the current understanding of both canonical and noncanonical miRNA biogenesis pathways in mammals. We also highlight the available computational tools and algorithms for miRNA target prediction. Finally, we emphasis the various miRNA therapeutic strategies.

Keywords: miRNA; miRNA Biogenesis; miRNA Therapeutics


  1. J Makarova., et al. “Circulating micrornas”. Biochemistry (Moscow) 80.9 (2015): 1117-1126.
  2. R W Carthew and E J J C Sontheimer. “Origins and mechanisms of miRNAs and siRNAs”. Cell 4 (2009): 642-655.
  3. L Li., et al. “Computational approaches for microRNA studies: a review”. Mamm Genome1 (2010): 1-12.
  4. P J M i c b Anderson. “Mutagenesis”. 48 (1995): 31-58.
  5. R C Lee., et al. “The elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14”. Cell 75.5 (1993): 843-854.
  6. B Wightman., et al. “Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in elegans”. 75.5 (1993): 855-862.
  7. B J Reinhart., et al. “The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans”. Nature 6772 (2000): 901-906.
  8. A Udgata., et al. “Transduction of functionally contrasting signals by two mycobacterial PPE proteins downstream of TLR2 receptors”. Journal of Immunology5 (2016): 1776-1787.
  9. S Li and D J J C R Patel. “Drosha and Dicer: Slicers cut from the same cloth”. Cell Research5 (2016): 511-512.
  10. X Tang., et al. “Phosphorylation of the RNase III enzyme Drosha at Serine300 or Serine302 is required for its nuclear localization”. Nucleic Acids Research19 (2010): 6610-6619.
  11. S C Kwon., et al. “Structure of human DROSHA”. Cell 1-2 (2016): 81-90.
  12. R Senturia., et al. “Structure of the dimerization domain of DiGeorge critical region 8”. Protein Science7 (2010): 1354-1365.
  13. T A Nguyen., et al. “Functional anatomy of the human microprocessor”. Cell 6 (2015): 1374-1387.
  14. A M Denli., et al. “Processing of primary microRNAs by the Microprocessor complex”. Nature 7014 (2004): 231-235.
  15. X Zhang and Y J N a r Zeng. “The terminal loop region controls microRNA processing by Drosha and Dicer”. Nucleic Acids Research21 (2010): 7689-7697.
  16. W Fang and D P J M c Bartel. “The menu of features that define primary microRNAs and enable de novo design of microRNA genes”. Molecular Cell1 (2015): 131-145.
  17. MS Song and J J J B j Rossi. “Molecular mechanisms of Dicer: endonuclease and enzymatic activity”. Biochemical Journal10 (2017): 1603-1618.
  18. I J MacRae., et al. “Structural basis for double-stranded RNA processing by Dicer”. Science 5758 (2006): 195-198.
  19. H Zhang., et al. “Single processing center models for human Dicer and bacterial RNase III”. Cell1 (2004): 57-68.
  20. M Jinek., et al. “A three-dimensional view of the molecular machinery of RNA interference”. Nature 7228 (2009): 405-412.
  21. G Meister., et al. “Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs”. Molecular Cell2 (2004): 185-197.
  22. A Khvorova., et al. “Functional siRNAs and miRNAs exhibit strand bias”. Cell2 (2003): 209-216.
  23. E Berezikov., et al. “Mammalian mirtron genes”. Molecular Cell2 (2007): 328-336.
  24. S Lin and R I J N r c Gregory. “MicroRNA biogenesis pathways in cancer”. 15.6 (2015): 321-333.
  25. Y Lee., et al. “The nuclear RNase III Drosha initiates microRNA processing”. Nature6956 (2003): 415-419.
  26. J Han., et al. “The Drosha-DGCR8 complex in primary microRNA processing”. Genes and Development24 (2004): 3016-3027.
  27. C Okada., et al. “A high-resolution structure of the pre-microRNA nuclear export machinery”. Science 5957 (2009): 1275-1279.
  28. E Lund and J Dahlberg. “Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs". in Cold Spring Harbor Symposia on Quantitative Biology 71 (2006): 59-66.
  29. A Grishok., et al. “Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control elegans developmental timing”. Cell 106.1 (2001): 23-34.
  30. M Yoda., et al. “ATP-dependent human RISC assembly pathways”. Nature Structural and Molecular Biology 1 (2010): 17-23.
  31. C N Weiss., et al. “A macro view of microRNAs: the discovery of microRNAs and their role in hematopoiesis and hematologic disease”. 334 (2017): 99-175.
  32. J G Ruby., et al. “Intronic microRNA precursors that bypass Drosha processing”. Nature 7149 (2007): 83-86.
  33. JS Yang., et al. “Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis”. PNAS 34 (2010): 15163-15168.
  34. J O'Brien., et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation”. Frontiers in Endocrinology (Lausanne) 9 (2015): 402.
  35. A Fire., et al. “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans”. Nature 391.6669 (1998): 806-811.
  36. E Huntzinger and E J N R G Izaurralde. “Gene silencing by microRNAs: contributions of translational repression and mRNA decay”. Nature Reviews Genetics2 (2011): 99-110.
  37. W Xu., et al. “Identifying microRNA targets in different gene regions”. BMC Bioinformatics7 (2014): 1-11.
  38. J Zhang., et al. “Oncogenic role of microRNA-532‑5p in human colorectal cancer via targeting of the 5'UTR of RUNX3”. Oncology Letter5 (2018): 7215-7220.
  39. A Dharap., et al. “MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene”. 8.11 (2013): e79467.
  40. HS Guo., et al. “MicroRNA directs mRNA cleavage of the transcription factor NAC1 to downregulate auxin signals for Arabidopsis lateral root development”. Plant Cell5 (2005): 1376-1386.
  41. A J Giraldez., et al. “Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs”. Science 5770 (2006): 75-79.
  42. R C Friedman., et al. “Most mammalian mRNAs are conserved targets of microRNAs”. Genome Research1 (2009): 92-105.
  43. S H Aghaee-Bakhtiari., et al. “miRandb: a resource of online services for miRNA research”. Briefings in Bioinformatics 2 (2018): 254-262.
  44. M Reczko., et al. “Functional microRNA targets in protein coding sequences”. Bioinformatics6 (2012): 771-776.
  45. A Kozomara and S J N a r Griffiths-Jones. “miRBase: integrating microRNA annotation and deep-sequencing data”. Nucleic Acids Research 39 (2010).
  46. A Kozomara., et al. “miRBase: from microRNA sequences to function”. Nucleic Acids ResearchD1 (2019): D155-D162.
  47. J Hanna., et al. “The potential for microRNA therapeutics and clinical research”. 10 (2019): 478.
  48. S Naidu., et al. “MiRNA-based therapeutic intervention of cancer”. Journal of Hematology and Oncology1 (2015): 1-8.
  49. A M McDermott., et al. “The therapeutic potential of microRNAs: disease modulators and drug targets”. Pharmaceutical Research12 (2011): 3016-3029.
  50. AF Christopher., et al. “MicroRNA therapeutics: discovering novel targets and developing specific therapy”. 7.2 (2016): 68.
  51. R Garzon., et al. “MicroRNA 29b functions in acute myeloid leukemia”. Blood26 (2009): 5331-5341.
  52. B Vester and J J B Wengel. “LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA”. Biochemistry42 (2004): 13233-13241.
  53. A Griveau., et al. “Silencing of miR-21 by locked nucleic acid–lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death”. International Journal of Pharmaceutics2 (2013): 765-774.
  54. M S Ebert., et al. “MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells”. Nature Methods 9 (2007): 721-726.
  55. L Ma., et al. “miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis”. Nature Cell Biology3 (2010): 247-256.
  56. Z Wang. “The principles of MiRNA-masking antisense oligonucleotides technology". in MicroRNA and Cancer: Springer, (2011): 43-49.
  57. F Abdallah and C J I R Pichon. “MicroRNAs in skin biology: Biogenesis, regulations and functions in homeostasis and diseases”. 15.1 (2019): 1-19.
  58. J A Weber., et al. “The microRNA spectrum in 12 body fluids”. Clinical Chemistry11 (2010): 1733-1741.
  59. A V Kristen., et al. “Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis”. Neurodegenerative Disease Management1 (2019): 5-23.
  60. D Ghosh., et al. “Combination therapy to checkmate Glioblastoma: clinical challenges and advances”. Clinical and Translational Medicine1 (2018): 1-12.
  61. G Reid., et al. “Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer”. Epigenomics8 (2016): 1079-1085.
  62. C J de Gooijer., et al. “Current chemotherapy strategies in malignant pleural mesothelioma”. 7.5 (2018): 574.


Citation: Prakash Koringa., et al. “miRNA: A Prospective Tool for Gene Regulation".Acta Scientific Veterinary Sciences 4.11 (2022): 13-22.


Copyright: © 2022 Prakash Koringa., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.008

Indexed In

News and Events

Contact US